Table 1 Correlation of miR-155 expression with clinicopathological factors of ATC patients
From: MiR-155 promotes anaplastic thyroid cancer progression by directly targeting SOCS1
Parameters | Patients | miR-155 | P |
|---|---|---|---|
Total | 31 | ||
Gender | 0.942 | ||
Male | 5 (16.1) | 3.46 ± 1.52 | |
Female | 26 (83.9) | 3.15 ± 1.06 | |
Age (Y) | 0.513 | ||
≥ 45 | 16 (51.6) | 3.34 ± 1.18 | |
< 45 | 15 (48.4) | 3.10 ± 1.07 | |
Tumor size,cm | 0.204 | ||
≥ 2 | 25 (80.6) | 3.36 ± 1.20 | |
< 2 | 6 (19.4) | 2.71 ± 0.98 | |
Extrathyroidal invasion | 0.033 | ||
Yes | 24 (77.4) | 3.78 ± 1.24 | |
No | 7 (22.6) | 1.47 ± 0.51 | |
Multicentricity | 0.142 | ||
Yes | 17 (54.8) | 3.41 ± 1.21 | |
No | 14 (45.2) | 2.95 ± 1.01 | |
Cervical metastasis status | 0.021 | ||
N+ | 22 (44.7) | 4.16 ± 1.38 | |
N- | 9 (55.3) | 1.35 ± 0.47 |